Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure–response relationship for progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Mo, Gary, Baldwin, John R., Peterson, Patrick M., Ilaria, Robert L., Conti, Ilaria, Cronier, Damien M., Tap, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373189/
https://www.ncbi.nlm.nih.gov/pubmed/30406840
http://dx.doi.org/10.1007/s00280-018-3723-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373189/
https://www.ncbi.nlm.nih.gov/pubmed/30406840
http://dx.doi.org/10.1007/s00280-018-3723-4

Ejemplares similares